Litigation Details for Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2014)

Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2014)

Docket	1:14-cv-00789	Date Filed	2014-06-20
Court	District Court, D. Delaware	Date Terminated	2015-09-23
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,501,730
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-20				External link to document

Litigation summary and analysis for: Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2014)

Last updated: July 7, 2026

Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (1:14-cv-00789): Litigation Summary, Patent Claims, Procedural Posture, and Expected Generic Launch Impact

Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc., 1:14-cv-00789, is a Hatch-Waxman patent infringement dispute tied to Otsuka’s branded product(s) and Par’s proposed generic. The litigation framework follows the standard FDA Orange Book plus 35 U.S.C. § 271(e)(2) structure: Otsuka asserts listed patents, Par responds with non-infringement and/or invalidity defenses, and the case outcome determines whether Par can launch its “at risk” product during remaining statutory exclusivity or patent life.

What patents are asserted in Otsuka v. Par Pharmaceutical 1:14-cv-00789?

Answer: The asserted patent(s) are the Orange Book listed patents Otsuka identifies as being infringed by Par’s ANDA product. The case caption alone (1:14-cv-00789) is not sufficient to enumerate the asserted patent numbers, claims, or specific formulation or method-of-use elements.

Which patent types are typically at issue in Otsuka vs. Par ANDA cases?

Otsuka’s ANDA patent litigations in the depression, pain, and neuropsychiatry spaces often involve one or more of:

• Formulation and release-rate patents for extended-release or specialty dosage forms.
• Method-of-use patents tied to approved dosing regimens or indications.
• Manufacturing and process patents governing particle engineering or scale-up conditions.
• Polymorph/solid-state patents relevant to drug substance form.

How do complaint allegations map to Hatch-Waxman infringement theories?

In 35 U.S.C. § 271(e)(2) cases, plaintiffs typically plead:

• Technical infringement by the proposed generic product.
• Submission-based infringement tied to the ANDA contents.
• Patent-validity challenges raised by the generic in response.

Claim-by-claim infringement and invalidity

Without the docket’s specific filings (complaint, amended complaint, claim charts, Markman orders), the infringement/invalidity positions cannot be stated accurately for this docket number.

How does 1:14-cv-00789 procedural posture drive the outcome?

Answer: Procedural outcomes in Hatch-Waxman cases usually turn on claim construction and summary judgment scheduling, followed by trial only if material factual disputes remain.

Typical milestones for this case type

For ANDA-driven infringement suits, the case usually proceeds through:

• Early pleadings and exhibit-based infringement allegations.
• Claim construction (often through Markman).
• Motions to dismiss or transfer (sometimes).
• Summary judgment on infringement/invalidity.

What happens if the court grants summary judgment vs. denies it?

• Plaintiff win (infringement and/or validity): blocks launch until patent expiration or settlement agreement terms.
• Defendant win (invalidity/non-infringement): permits launch if no additional patents block.

When do settlements occur in this docket class?

Settlements commonly occur:

• After Markman but before final judgment.
• After key invalidity rulings.
• Near FDA eligibility for approval and/or launch timing.

When does Otsuka’s exclusivity end relative to generic entry risks in 1:14-cv-00789?

Answer: Exclusivity timing depends on (i) the asserted patent expiration dates and (ii) any separate statutory exclusivity (5-year new chemical entity, 3-year new clinical investigation, orphan, or pediatric extensions) tied to the NDA referenced by the ANDA.

What governs “entry risks”

Launch timing is driven by:

• Patent expiration (including terminal disclaimers).
• Any pediatric exclusivity extension.
• Remaining exclusivity periods independent of patents.
• Whether the case ends in injunction or a consent-to-launch arrangement.

Why docket-specific dates matter

Even when two suits share the same parties, exclusivity can differ by:

• NDA vs. 505(b)(2) vs. ANDA reference.
• Different strengths, dosage forms, or submission amendments.
• Different Orange Book patent lists and “section viii” updates.

What is the Orange Book status of Otsuka’s product in 1:14-cv-00789?

Answer: Orange Book status cannot be reproduced from the docket number alone. Orange Book status requires the exact NDA number and listed patent identifiers for the Otsuka drug and strength(s) that Par targeted in its ANDA.

How Orange Book listings create litigation leverage

The patent list entries define:

• Whether a Paragraph IV certification was filed.
• Whether the case was triggered by a “high bar” for validity/infringement.
• What patents remain active if some claims are dismissed.

Which company(s) are challenging Otsuka in this case, and what does that mean commercially?

Answer: The defendant is Par Pharmaceutical Inc. The parties and commercial impact are typical: Par’s proposed generic entry date and manufacturing readiness determine how much of Otsuka’s revenue is at risk during any window after litigation resolution.

Commercial exposure pathways

• If Otsuka’s patent(s) are upheld, Par’s entry is delayed, preserving branded market share.
• If Otsuka’s patent(s) fall, Par can launch upon FDA approval and avoid further blocking injunctions unless additional patents are asserted elsewhere.

How strong is Otsuka’s patent estate in Otsuka v. Par Pharmaceutical Inc. (1:14-cv-00789)?

Answer: Strength cannot be assessed without the asserted patent numbers, their remaining term at filing, claim scope, and the court’s holdings.

Strength indicators used in practice

For Hatch-Waxman cases, strength is judged by:

• Remaining life at filing and at decision.
• Prior art density and obviousness exposure for formulation/process claims.
• Claim construction outcomes (especially for “means plus function,” structural limitations, and functional release language).
• Whether Otsuka’s asserted claims cover the proposed generic’s exact release profile and formulation characteristics.

Litigation outcome is the real “strength” metric

In these cases, “strength” is ultimately reflected by:

• Whether the court finds infringement.
• Whether invalidity arguments survive.
• Whether settlement forces a delayed launch.

What patent litigation affects the same product family and could block generic entry anyway?

Answer: Other patents may exist for the same NDA (or for different strengths/dosage forms) even if one patent is struck or expires. The docket number alone does not enumerate parallel actions.

Common blocking scenarios

• Separate lawsuits against other generic filers for additional Orange Book patents.
• Additional patents asserted in the same suit but later narrowed.
• Revisions to Par’s ANDA submission leading to amended certifications.

What are likely the end-game outcomes in this docket?

Answer: In Hatch-Waxman cases, the end game usually resolves into one of three outcomes:

1. Injunction or continued blocking until patent expiration.
2. Consent to launch on a later date with royalty or non-exclusive license terms.
3. Early entry if all asserted patents are found invalid or not infringed.

Settlement mechanics that matter to market entry

When settlements occur, they typically include:

• Launch date.
• Covenant not to sue (or stipulation of dismissal).
• Royalty and reporting provisions.
• Limits on additional patent challenges.

Key timeline (litigation-driven) for 1:14-cv-00789

Answer: A docket-level timeline requires the court’s filings. The filing date (“1:14-cv-00789”) indicates initiation in 2014, but exact dates for complaint, answers, claim construction, summary judgment, trial, and final judgment cannot be accurately stated without docket document data.

Key Takeaways

• 1:14-cv-00789 is a Hatch-Waxman-style patent dispute where Par’s ANDA challenged Otsuka’s Orange Book-listed patents, triggering a 35 U.S.C. § 271(e)(2) infringement case.
• Litigation resolution governs whether Par can launch and when, based on court findings or settlement terms.
• Specific patent numbers, claim scope, and procedural milestones are not derivable from the docket number alone.

FAQs

What is 1:14-cv-00789 and what claim type does it involve?

It is the case designation for a patent infringement action brought under the Hatch-Waxman framework, typically asserted under 35 U.S.C. § 271(e)(2) tied to an ANDA.

Does the docket guarantee a Paragraph IV certification?

Hatch-Waxman infringement suits of this sort ordinarily follow Paragraph IV structure tied to Orange Book patents, but that cannot be confirmed from the docket number alone.

Can a settlement allow generic entry before full patent expiration?

Yes. Settlements commonly set an agreed launch date earlier than full expiration, conditioned on covenants and sometimes royalty terms, depending on the patents at issue.

Does this case affect multiple strengths or only one dosage form?

Often only the litigated product and strength(s) in the ANDA are covered, but the exact scope depends on the asserted claims and Par’s submission.

What other legal levers can delay Par’s launch even if one patent falls?

Other Orange Book patents, statutory exclusivities, or parallel litigations can still block launch unless all listed blockers for the relevant ANDA are cleared.

References

1. United States District Court docket Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc., 1:14-cv-00789. (Court docket reference).